Izalontamab brengitecan
- Generic Name
- Izalontamab brengitecan
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05785039
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, Shanghai, China
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05470348
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Fudan University ShangHai Cancer Center, Shanghai, Shanghai, China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
- Conditions
- Locally Advanced or Metastatic Urinary TumorsOther Solid Tumors
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05393427
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT05262491
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Jinan Central Hospital, Jinan, Shandong, China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT05194982
- Locations
- 🇨🇳
Shanxi Cancer Hospital, Taiyuan, Shanxi, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.